Scienture Holdings Q1 revenue jumps on Arbli sales, operating expenses steady

Scienture Holdings

18/05/2026 13:47

Overview

US specialty pharma firm's Q1 revenue rose 449% yr/yr on increased Arbli product orders

Gross margin expanded to 95.6% from 6.6% on higher Arbli sales

Company posted Q1 net loss of $3.4 mln as operating expenses held steady

Outlook

Company expects launch of REZENOPY(TM) to impact results in second half of 2026

Scienture says recent debt financing supports growth and financial flexibility

Company aims for profitability in 2027

Result Drivers

ARBLi ORDERS - Q1 revenue and gross margin gains driven by incremental product orders for Arbli, following its commercial launch in late 2025

PRESCRIPTION GROWTH - Company saw continued month-over-month growth in both prescriptions and units sold for Arbli

Company press release: ID:nGNX5RGbB1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Gross Margin
95.6%
Q1 Gross Profit
$54,000
Q1 Operating Expenses
$3.56 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Scienture Holdings Inc is $1.50, about 272.2% above its May 15 closing price of $0.40

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)